KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.45

Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study).

X Serra-Aracil, C Pericay, J Badia-Closa, T Golda, S Biondo, P Hernández, E Targarona, N Borda-Arrizabalaga, A Reina, S Delgado, F Vallribera, A Caro, J Gallego-Plazas, M Pascual, C Álvarez-Laso, H G Guadalajara-Labajo, L Mora-Lopez

Ann Oncol 34(1) 78-90

PMID36220461
PMCID-
DOI10.1016/j.annonc.2022.09.160
发表日期2022-10-11
入排依据:The trial is a randomized Phase III oncology study in humans, but the abstract reports only short-term morbidity and pathological outcomes. It explicitly states that cancer outcome results (which would include time-to-event endpoints) are pending. The intervention includes chemoradiotherapy, but the trial's primary comparison is between two surgical strategies (local excision vs. total mesorectal excision), and the abstract does not present the time-to-event efficacy data required for inclusion.
摘要

摘要

BACKGROUND: The standard treatment of T2-T3ab,N0,M0 rectal cancers is total mesorectal excision (TME) due to the high recurrence rates recorded with local excision. Initial reports of the combination of pre-operative chemoradiotherapy (CRT) and transanal endoscopic microsurgery (TEM) have shown reductions in local recurrence. The TAU-TEM study aims to demonstrate the non-inferiority of local recurrence and the improvement in morbidity achieved with CRT-TEM compared with TME. Here we describe morbidity rates and pathological outcomes. PATIENTS AND METHODS: This was a prospective, multicentre, randomised controlled non-inferiority trial including patients with rectal adenocarcinoma staged as T2-T3ab,N0,M0. Patients were randomised to the CRT-TEM or the TME group. Patients included, tolerance of CRT and its adverse effects, surgical complications (Clavien-Dindo and Comprehensive Complication Index classifications) and pathological results (complete response in the CRT-TEM group) were recorded in both groups. Patients attended follow-up controls for local and systemic relapse. TRIAL REGISTRATION: NCT01308190. RESULTS: From July 2010 to October 2021, 173 patients from 17 Spanish hospitals were included (CRT-TEM: 86, TME: 87). Eleven were excluded after randomisation (CRT-TEM: 5, TME: 6). Modified intention-to-treat analysis thus included 81 patients in each group. There was no mortality after CRT. In the CRT-TEM group, one patient abandoned CRT, 1/81 (1.2%). The CRT-related morbidity rate was 29.6% (24/81). Post-operative morbidity was 17/82 (20.7%) in the CRT-TEM group and 41/81 (50.6%) in the TME group (P < 0.001, 95% confidence interval 42.9% to 16.7%). One patient died in each group (1.2%). Of the 81 patients in the CRT-TEM group who received the allocated treatment, 67 (82.7%) underwent organ preservation. Pathological complete response in the CRT-TEM group was 44.3% (35/79). In the TME group, pN1 were found in 17/81 (21%). CONCLUSION: CRT-TEM treatment obtains high pathological complete response rates (44.3%) and a high CRT compliance rate (98.8%). Post-operative complications and hospitalisation rates were significantly lower than those in the TME group. We await the results of the follow-up regarding cancer outcomes and quality of life.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。